Introduction {#s1}
============

Cancer is a major public health problem and one of the principal causes of death worldwide [@pone.0082855-Siegel1]. It is predicted that the number of newly diagnosed cancers in the world will increase to more than 15 million and 12 million people will die of cancer in 2020[@pone.0082855-Kanavos1]. It has been widely accepted that carcinogenesis is a consequence of complex inherited and environmental factors. However, the exact mechanism of carcinogenesis remains largely unknown. Epidemiological study points a connection between chronic inflammation and various cancers [@pone.0082855-Balkwill1], and it is estimated that 15--20% of all deaths from cancer are associated with infections and inflammatory responses [@pone.0082855-Mantovani1]

Monocyte chemo-attractant protein 1 (MCP-1), also known as CCL-2 (CC chemokine ligand 2), is a member of the CC chemokine family which plays an important role in inflammation, and is encoded by the CCL-2 gene which locates on 17q11.2-q12 [@pone.0082855-Rollins1]--[@pone.0082855-Craig1]. MCP-1is involved in a series of diseases including rheumatoid arthritis, chronic obstructive pulmonary disease, cardiovascular disease, and cancer [@pone.0082855-Conti1]. Being a chemokine, MCP-1 is largely produced by cancer cells and is responsible for the recruitment of macrophages to many kinds of tumors, including cancers of ovary, breast, bladder, lung, and cervix [@pone.0082855-Negus1]-[@pone.0082855-Riethdorf1], and high concentrations of tumor-associated macrophages (TAMs) are linked to better tumor growth and progression as well as poor prognosis [@pone.0082855-Mantovani2]. Therefore, MCP-1 may play a critical role in tumor initiation, promotion, and progression [@pone.0082855-BektasKayhan1].

Several MCP-1 polymorphisms have been reported to be associated with disease susceptibility or severity [@pone.0082855-Pandith1], and the −2518A/G (rs1024611) polymorphism which can increase the expression of MCP-1 was most widely studied [@pone.0082855-Rovin1]. Recently, an increasing number of studies have examined the association between this −2518A/G polymorphism and cancer risk [@pone.0082855-BektasKayhan1]--[@pone.0082855-Landi1]. However, individual study may have insufficient power to obtain a comprehensive and reliable conclusion. We, therefore, performed a meta-analysis by pooling all eligible studies to clarify this inconsistency and to achieve a more precise estimation of the relationship between the MCP-1 −2518A/G polymorphism and cancer risk.

Methods {#s2}
=======

Identification and eligibility of relevant studies {#s2a}
--------------------------------------------------

A systematic search of PubMed and China National Knowledge Infrastructure (CNKI) database (last search updated in June 2013) was carried out to identify case-control studies that investigated the association between the −2518A/G polymorphism and cancer risk. The search strategy was based on combinations of "MCP-1", "CCL-2"; "cancer", "carcinoma", "tumor"; "polymorphism", "variant", "SNP". In order to minimize potential publication bias, citations in original studies were also screened by manual search to identify additional relevant publications. The selection criteria of the retrieved articles in our meta-analysis were as follows: (1) a case--control design; (2) investigating the −2518A/G polymorphism and cancer risk; (3) sufficient data available to calculate an odds ratio (OR) with 95% confidence interval (CI). The major reasons for exclusion of studies were (1) investigations in subjects with cancer-prone disposition; (2) overlapping data; (3) not published in English and Chinese.

Data extraction {#s2b}
---------------

The following information was collected independently by two of the authors (Da and Zhang) for each eligible study: name of first author, published year, country of origin, ethnicity, source of control, cancer type, genotyping method, total number of genotyped cases and controls, genotype frequencies in cases and control, and Hardy--Weinberg equilibrium (HWE) of controls. Ethnicity was categorized as Asian, Caucasian and mixed population. Cancer types were classified as bladder cancer, prostate cancer, digestive system cancer (oral cancer, gastric cancer, colorectal and hepatocellular cancer), and other cancers. All studies were defined as hospital-based (HB) or population-based (PB) according to the source of control. The final results of data extraction were compared carefully, and any disagreements were discussed until reaching conformity on all items among all authors.

Statistical analysis {#s2c}
--------------------

For each study, deviation from HWE among controls was evaluated by Pearson\'s χ^2^-test and a *P*\<0.05 was considered as significant disequilibrium. The strength of the associations between the −2518A/G polymorphism and cancer susceptibility was measured by OR with its 95%CI. The pooled ORs and the 95% CIs in each comparison were calculated using the following models: homozygote model (GG vs. AA), heterozygote model (AG vs. AA), dominant model (GG/AG vs. AA) and recessive model (GG vs. AG/AA), respectively. Between-study heterogeneity was assessed by the chi-square based Q test and the heterogeneity was found to be significant when *P*\<0.10[@pone.0082855-Lau1]. The summary ORs were calculated by the fixed-effects model (Mantel-Haenszel method) when the *P* value was \>0.10. Otherwise, the random-effects model (DerSimoniane-Laird method) was utilized [@pone.0082855-DerSimonian1]. The Z test was applied to determine the significance of the pooled ORs. And a P\<0.05 was considered significant. Sub-group analyses and meta-regression were carried out to explore the source of heterogeneity among variables, including ethnicity, cancer types, source of control and sample size (studies with more than 500 participants were defined as "large", and studies with less 500 participants were defined as "small"), respectively. Sensitivity analyses were performed by sequentially removing individual study to evaluate the robustness of the overall estimate. Finally, publication bias was examined by Begg\'s funnel plot and the Egger\'s linear regression test, and a *P*\<0.05 was considered to be representative of statistically significant publication bias [@pone.0082855-Egger1]. All p-values were two sided, and any statistical tests for this meta-analysis were done with STATA statistical software (version 12.0; StataCorp, College Station, Texas USA).

Results {#s3}
=======

Characteristics of eligible studies {#s3a}
-----------------------------------

After careful retrieve and selection, 18 eligible articles were identified according to inclusion and exclusion criteria. The study selection procedures were shown in [Figure 1](#pone-0082855-g001){ref-type="fig"}. Two types of cancers were reported in Qin\'s study, and we extracted data separately for each cancer. Therefore, a total of 19 case-control studies with 4,162 cases and 5,173 controls were included in this meta-analysis.

![Flow diagram of the study selection process.\
\*a total of 18 articles were identified and two types of cancers were reported in one article, we extracted data separately for each cancer, thus 19 studies were eligible.](pone.0082855.g001){#pone-0082855-g001}

Out of the 19 applicable studies, 17 were published in English and 2 were written in Chinese, 10 of them were studies of Asians, 8 studies of Caucasian and one study of mixed population. According to the source of control, 10 studies were hospital-based and 9 were population-based. The genotype distributions in the controls were in agreement with HWE except for two studies (Gu [@pone.0082855-Gu1], p\<0.01; Attar [@pone.0082855-Attar1], p = 0.04). The genotyping methods in studies were nearly all polymerase chain reaction-restriction fragment length polymorphism. The detailed characteristics of each case-control study were listed in [Table 1](#pone-0082855-t001){ref-type="table"}.

10.1371/journal.pone.0082855.t001

###### Characteristics of the eligible studies in the meta-analysis.

![](pone.0082855.t001){#pone-0082855-t001-1}

  Study              Year   Country   Ethnicity    Cancer type     Control source   No. of case/control   Case   Control   HWE                    
  ----------------- ------ --------- ----------- ---------------- ---------------- --------------------- ------ --------- ----- ----- ----- ----- -----
  Liu                2013    China      Asian         Renal              HB               416/458          59      197     160   93    234   131   Yes
  Arshad             2013    India      Asian        Bladder             PB               120/190          32      64      24    60    87     8    Yes
  Wu                 2013   Taiwan      Asian        Cervical            HB               86/253           16      52      18    33    132   88    Yes
  Kucukgergin        2012   Turkey    Caucasian      Bladder             HB               142/197          67      54      21    96    83    18    Yes
  Singh              2012    India      Asian        Bladder             HB               200/200          83      101     16    81    97    22    Yes
  Kuckergergin       2012   Turkey    Caucasian      Prostate            HB               156/152          78      67      11    64    71    17    Yes
  Bektas-Kayhan      2012   Turkey    Caucasian        Oral              HB               129/140          67      56       6    94    45     1    Yes
  Chen               2011   Taiwan      Asian          Oral              HB               216/344          49      112     55    80    172   92    Yes
  Gu                 2011    China      Asian        Gastric             HB               608/608          94      270     244   138   268   202   No
  Kruszyna           2011   Poland    Caucasian       Breast             PB               160/323          89      54      17    154   145   24    Yes
  Yeh                2010   Taiwan      Asian     Hepatocellular         HB               102/344          23      48      31    80    172   92    Yes
  Yang               2010    China      Asian          Lung              PB               112/82           34      48      30    10    34    38    Yes
  Narter             2010   Turkey    Caucasian      Bladder             PB                72/76           48      16       8    40    33     3    Yes
  Attar              2010   Turkey    Caucasian    Endometrial           HB               50/211           26      17       7    124   82     5    No
  Qin                2009    China      Asian     Hepatocellular         PB               397/471         133      182     82    185   225   61    Yes
  Qin                2009    China      Asian     Nasopharyngeal         PB               575/471         185      299     91    185   225   61    Yes
  Vazquez-Lavista    2009   Mexico      Mixed        Bladder             PB               47/126           9       35       3    18    71    37    Yes
  Sáenz-López        2008    Spain    Caucasian      Prostate            PB               298/311         174      100     24    178   123   10    Yes
  Landi              2006    Spain    Caucasian     Colorectal           HB               276/251         161      97      18    138   97    16    Yes

PB: population-based; HB: hospital-based; HWE: Hardy--Weinberg equilibrium

Meta-analysis results {#s3b}
---------------------

Overall, there was no statistically significant association between cancer risk and the −2518A/G polymorphisms in all genetic models ([Table 2](#pone-0082855-t002){ref-type="table"}). However, strong evidence of heterogeneity was found in each comparison. Thus, sub-group analyses were performed to determine the influence of confounding factors.

10.1371/journal.pone.0082855.t002

###### Meta-analysis of the association between the MCP-1 −2518A/G polymorphism and cancer risk in all genetic models.

![](pone.0082855.t002){#pone-0082855-t002-2}

                                        GG vs. AA          AG vs. AA    GG/AG vs. AA     GG vs. AG/AA                                                              
  ------------------------- ---- ------------------------ ----------- ----------------- -------------- ------------------------ --------- ------------------------ ---------
  Total                      20      1.28(0.95,1.73)        \<0.001    1.00(0.86,1.16)      0.004          1.05(0.89,1.23)       \<0.001      1.25(0.97,1.60)       \<0.001
  Cancer type                                                                                                                                                      
  Digestive system cancer    6    **1.43(1.05,1.96)\***      0.081     1.17(0.95,1.43)      0.149          1.24(0.99,1.56)        0.050    **1.29(1.02,1.64)\***     0.141
  Bladder cancer             5       1.26(0.47,3.42)        \<0.001    0.92(0.66,1.30)      0.124          0.99(0.70,1.39)        0.089       1.25(0.46,3.39)       \<0.001
  Prostate cancer            2       1.15(0.26,5.16)         0.008     0.81(0.62,1.07)      0.808          0.87(0.67,1.13)        0.337       1.27(0.30,5.39)        0.008
  Others                     6       1.13(0.59,2.16)        \<0.001    0.90(0.63,1.29)      0.005          0.93(0.63,1.38)       \<0.001      1.17(0.71,1.92)       \<0.001
  Ethnicity                                                                                                                                                        
  Asian                      10      1.22(0.84,1.76)        \<0.001    1.15(0.98,1.35)      0.142          1.16(0.94,1.43)        0.003       1.16(0.88,1.52)       \<0.001
  Caucasian                  8       1.67(0.99,2.80)         0.012     0.85(0.67,1.07)      0.048          0.94(0.75,1.18)        0.040    **1.81(1.10,2.96) \***    0.015
  Source of control                                                                                                                                                
  PB                         9       1.50(0.86,2.64)        \<0.001    0.88(0.67,1.15)      0.003          0.97(0.74,1.27)        0.001       1.57(0.94,2.61)       \<0.001
  HB                         10      1.12(0.80,1.58)         0.001     1.09(0.92,1.29)      0.152          1.11(0.90,1.36)        0.008       1.07(0.83,1.39)        0.005
  Sample size                                                                                                                                                      
  Large^a^                   7    **1.59(1.29,1.96) \***     0.173     1.13(0.96,1.34)      0.108       **1.22(1.03,1.45) \***    0.054    **1.38(1.15,1.66) \***    0.124
  Small^b^                   12      1.12(0.63,1.99)        \<0.001    0.88(0.70,1.11)      0.026          0.91(0.71,1.17)        0.002       1.19(0.72,1.97)       \<0.001

N: number of studies; OR: odds ratio; P~h~: p value for heterogeneity; **\*OR** with statistical significance; PB: population-based; HB: hospital-based; a: studies with more than 500 participants; b: studies with less than 500 participants.

As for cancer type, a statistically increased cancer risk was found in the comparison of homozygote (GG vs. AA: OR = 1.43, 95%CI = 1.05--1.96, P~heterogeneity~ = 0.08) and recessive model (GG vs. AG/AA: OR = 1.29, 95%CI = 1.02--1.64, P~heterogeneity~ = 0.14, [Figure 2](#pone-0082855-g002){ref-type="fig"}) for digestive system cancer. However, no significant associations were discovered in bladder cancer, prostate cancer or other cancers.

![Forest plot of recessive model for overall comparison by cancer type (GG vs. AG/AA).](pone.0082855.g002){#pone-0082855-g002}

When stratified by ethnicity, an increased cancer risk was found in the recessive model comparison for Caucasians (GG vs. AG/AA: OR = 1.81, 95%CI = 1.10--2.96, P~heterogeneity~ = 0.02, [Figure 3](#pone-0082855-g003){ref-type="fig"}), In Asians, however, no significant association but only a trend of increased cancer risk was found in each genetic model.

![Forest plot of recessive model for overall comparison by ethnicity (GG vs. AG/AA).](pone.0082855.g003){#pone-0082855-g003}

Further, in the stratified analyses by sample size and source of control, we observed a significantly increased risk in "large" studies in three genetic models: homozygote model (GG vs. AA: OR = 1.59, 95%CI = 0.74--2.05, P~heterogeneity~ = 0.17), recessive model (GG vs. AG/AA: OR = 1.38, 95%CI = 1.15--1.66, P~heterogeneity~ = 0.12) and dominant model (GG/AG vs. AA: OR = 1.22, 95%CI = 1.03--1.45, P~heterogeneity~ = 0.05). However, the cancer cases and controls did not significantly differ in the subgroup analyses according to the source of control.

Evaluation of heterogeneity {#s3c}
---------------------------

Between-study heterogeneity was obvious in each model ([Table 2](#pone-0082855-t002){ref-type="table"}). Meta-regression was further conducted to explore the sources of heterogeneity. The results indicated that cancer type (*P* = 0.02), but not ethnicity, source of control and sample size (*P*\>0.05) contributed to source of heterogeneity.

Sensitivity analysis and publication bias {#s3d}
-----------------------------------------

A one-way sensitivity analysis was performed to assess the stability of the results of the meta-analysis. Statistically similar results were obtained after sequentially excluding individual studies, which confirmed the robustness of the meta-analysis (data not shown). For publication bias, as shown in [Figure 4](#pone-0082855-g004){ref-type="fig"}, the shape of the funnel plot did not reveal any evidence of obvious asymmetry(GG vs. AG/AA: *P* = 0.67), and the results of Egger\'s test also indicated no risk of publication bias (GG vs. AG/AA: *P* = 0.96)

![Begg\'s funnel plot of MCP-1 −2518A/G polymorphism and cancer risk (GG vs. AG/ AA).](pone.0082855.g004){#pone-0082855-g004}

Discussion {#s4}
==========

The impacts of MCP-1 activation on tumor cells have been demonstrated in a variety of malignancies [@pone.0082855-Conti1]. It has been shown that the −2518A/G SNP in the regulatory region of MCP-1 gene could affect transcription and increase the expression of MCP-1[@pone.0082855-Rovin1]. MCP-1 expression was associated with tumorigenesis and metastasis of several solid tumors [@pone.0082855-Gu1]. The overexpression of MCP-1 has been reported in a wide range of tumors such as glioma, ovarian, esophageal, breast, lung, and prostate cancer [@pone.0082855-Melgarejo1]--[@pone.0082855-Lu1]. In the light of these findings, it is reasonable that the −2518A/G polymorphism may contribute to cancer susceptibility. However, previous case-control studies have yielded inconsistent conclusions. In order to obtain a more precise estimation of this relationship, we performed this meta-analysis including 19 case-control studies with 4,162 cases and 5,173 controls, and the result demonstrated that the MCP-1 −2518A/G polymorphism was not associated with cancer susceptibility in overall analysis.

Sub-group analysis was conducted to detect the effects of confounding factors. When stratified by ethnicity, there was a significantly increased cancer risk among Caucasians but not in Asians. The differences may be explained by genetic diversities, different risk factors in life styles, and the exposure to different environmental factors. However, it was noteworthy that an increased cancer risk was found in the recessive model for Caucasians, and only two "large" studies were included in this subgroup. It was reported that small size may decrease statistical power and even may produce a fluctuated risk estimate. Therefore, this relationship needs to be further confirmed in larger size, well-designed prospective studies.

In the subgroup analysis by cancer type, no significant association was found except for homozygote model and recessive model comparison of digestive system cancer. This could be explained by the following two reasons: one may be that this polymorphism may play a different role in different cancer sites. The other possible reason is that most studies in this subgroup were "large" studies which have sufficient statistical power to investigate a slight effect compared with "small" studies. In consistent with this explanation, there was a significantly increased cancer risk in "large" studies in three genetic models, but no significant association was observed in "small" studies in any comparison.

Finally, attention should be paid to the relatively huge heterogeneity in this meta-analysis. Meta-regression indicated that cancer type (*P* = 0.02), but not ethnicity, source of control or sample size (*P*\>0.05) contributed to the source of heterogeneity. In fact, numerous other factors including age, sex ratio, family history and lifestyle may also explain the heterogeneity. Unfortunately, we can not conduct a meta-regression utilizing these variables because detail information was not available.

Some limitations of this meta-analysis should be addressed. Firstly, only English and Chinese

papers were included in this meta-analysis,. Therefore, selection bias may have existed, although not any publication bias was showed in the funnel plot and Egger\'s tests. Secondly, this meta-analysis was based on unadjusted estimates, because adjusted estimates were not shown in all published studies. Thirdly, no genome-wide association studies (GWAS) date was included in this meta-analysis. As we know, as compared to the candidate-gene approach, GWAS have revolutionized the field of genetic susceptibility and provided a powerful approach to identify the common genetic variants. Therefore, this powerful and comprehensive approach have contributed to unprecedented advances in our understanding of the role of common genetic variation in various cancers[@pone.0082855-Zhong1]--[@pone.0082855-Wu2].However, due to the strict criteria, some low-risk alleles might be overlooked in spite of their potential importance in disease risk.

In conclusion, this meta-analysis suggests that the MCP-1 −2518A/G polymorphism may have some relation to digestive system cancer susceptibility or cancer development in Caucasian. To further confirm the results, large scale case-control studies with different ethnic groups and multiple cancer types are needed.
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